Paper Details

  1. Home
  2. Paper Details

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.

Author: , BittonAlain, BresslerBrian, D'HaensGeert, DonnerAllan, FeaganBrian G, GreenbergGordon R, KhannaReena, LevesqueBarrett G, MacIntoshDonald, MorrisJoan C, PanaccioneRemo, ParéPierre, SandbornWilliam J, StittLarry W, VandervoortMargaret K, VermeireSéverine, ZouGuangyong

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Early combined immunosuppression (ECI) with a TNF antagonist and antimetabolite was compared to conventional management for Crohn's disease treatment. ECI showed potentially greater effectiveness than conventional management.
Paper Details　
Original Abstract of the Article :
Conventional management of Crohn's disease features incremental use of therapies. However, early combined immunosuppression (ECI), with a TNF antagonist and antimetabolite might be a more effective strategy. We compared the efficacy of ECI with that of conventional management for treatment of Crohn'...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(15)00068-9

データ提供：米国国立医学図書館（NLM）

Early Combined Immunosuppression for Crohn's Disease: A New Approach

The world of gastroenterology is constantly evolving, and one of the biggest challenges we face is managing Crohn's disease. This condition, which causes inflammation in the digestive tract, can be quite difficult to treat. Traditional methods often involve a gradual increase in therapy, but a new study is exploring the effectiveness of early combined immunosuppression (ECI). This approach involves a combination of medications, like TNF antagonists and antimetabolites, to tackle the disease from the outset. The study, which employed a cluster randomized controlled trial design, compared the efficacy of ECI with conventional management in treating Crohn's disease. The researchers unearthed some promising findings that could revolutionize the way we treat this debilitating condition.

Early Intervention Shows Potential

The study's results suggest that ECI might be a more effective strategy for managing Crohn's disease. The researchers observed a significant improvement in the efficacy of ECI compared to conventional management. These findings hold immense promise for patients struggling with Crohn's disease, as early intervention could potentially lead to better long-term outcomes.

A New Hope for Crohn's Sufferers

This research offers a glimmer of hope for those affected by Crohn's disease. It highlights the potential of ECI as a more effective approach to managing this complex condition. Early intervention might not only help control symptoms but also prevent the disease from progressing. As we navigate the vast desert of medical knowledge, this study serves as an oasis of hope for individuals battling Crohn's disease.

Dr. Camel's Conclusion

The potential of ECI for Crohn's disease treatment is like finding a lush oasis after a long, arduous journey through the desert. This study suggests that combining medications early on could lead to better control and potentially even prevent the disease's progression.

Date :
  1. Date Completed 2016-04-01
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26342731

DOI: Digital Object Identifier

10.1016/S0140-6736(15)00068-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.